SKIL Antibody

What is SKIL/SnoN and what is its significance in cellular signaling?

SKIL, also known as SnoN, is a 77 kDa protein that functions as a critical mediator of the transforming growth factor-β (TGF-β) signaling pathway . The protein exhibits pro-oncogenic properties and plays significant roles in various cellular processes including embryonic development and tumorigenesis . SKIL/SnoN works by binding to Smad proteins, preventing their phosphorylation and subsequently inhibiting their ability to bind DNA and activate transcription of downstream genes . This makes SKIL a key negative regulator of TGF-β signaling, which has important implications for cancer research. The protein exists in at least four alternatively spliced isoforms: SnoN, SnoN2, SnoI, and SnoA .

SKIL demonstrates an interesting differential localization pattern that correlates with cell type and disease state. In cancer tissues and cell lines, SKIL is primarily located in the nucleus, whereas in normal tissues and primary epithelial cells, it is predominantly found in the cytoplasm . This subcellular localization shift may be relevant to its function in disease progression.

Western blot analysis has confirmed SKIL expression in multiple human cell lines and tissues including:

• A431 cells

• Human skeletal muscle tissue

• HepG2 cells

• MCF-7 cells

Immunohistochemistry has detected positive SKIL expression in human endometrial cancer tissue, with recommended antigen retrieval using TE buffer pH 9.0 or citrate buffer pH 6.0 .

How should SKIL antibody dilutions be optimized for different applications?

The optimization of SKIL antibody dilutions is critical for obtaining specific signals with minimal background. Based on validated protocols, the following methodological approach is recommended:

For Western Blot:

• Begin with a medium range dilution (1:2000) and test using positive control lysates (A431, HepG2, or MCF-7 cells)

• Generate a dilution series (e.g., 1:1000, 1:2000, 1:4000, 1:8000) to identify optimal signal-to-noise ratio

• Block membranes thoroughly (5% non-fat milk or BSA in TBST for 1 hour at room temperature)

• Include negative controls (cell lines with SKIL knockdown) to confirm specificity

For Immunohistochemistry:

• Start with a middle-range dilution (1:200)

• Critically evaluate antigen retrieval methods, comparing TE buffer pH 9.0 and citrate buffer pH 6.0

• Titrate antibody concentration based on signal intensity and background levels

• Always include positive control tissues (e.g., endometrial cancer tissue)

It is recommended that this reagent should be titrated in each testing system to obtain optimal results, as performance can be sample-dependent .

What controls and validation methods should be used for SKIL antibody experiments?

Proper validation of SKIL antibodies requires multiple complementary approaches:

Positive Controls:

• Cell lines: A431, HepG2, and MCF-7 cells have been validated for Western blot

• Tissues: Human endometrial cancer tissue for IHC; human skeletal muscle for Western blot

Negative Controls:

• SKIL knockdown or knockout cell lines (siRNA or CRISPR)

• Isotype control antibodies (rabbit IgG)

• Blocking peptide competition assays

Cross-Validation Approaches:

• Use multiple antibodies targeting different epitopes of SKIL

• Compare protein detection with mRNA expression data

• Validate subcellular localization using fractionation followed by Western blot

• For co-immunoprecipitation experiments, confirm interactions using reciprocal pull-downs

Several publications have used SKIL knockdown (KD) or knockout (KO) systems to validate antibody specificity, with at least one publication specifically documenting this approach .

How can SKIL antibodies be used to investigate its role in tumorigenesis and immune escape?

Recent research has revealed SKIL's significant role in tumorigenesis and immune escape, particularly in non-small-cell lung cancer (NSCLC) . Researchers can investigate these processes using the following methodological approaches:

For Tumorigenesis Studies:

• Assess SKIL expression levels in paired tumor and adjacent normal tissues using Western blot and IHC

• Correlate expression with clinical parameters and patient outcomes

• Use lentiviral vectors to modulate SKIL expression (overexpression/silencing) in cell lines

• Evaluate malignant phenotypes through:

  • Colony formation assays

  • Transwell migration/invasion assays

  • MTT proliferation assays

  • Xenograft mouse models

For Immune Escape Investigations:

• Implement syngeneic mouse models with SKIL-modulated tumor cells

• Analyze T cell infiltration using flow cytometry

• Examine the impact of SKIL on the STING pathway through quantitative PCR and Western blot

• Investigate the relationship between SKIL, autophagy, and immune surveillance using:

  • Co-immunoprecipitation to detect SKIL-TAZ interactions

  • Autophagy markers (LC3, p62) assessment

  • STING pathway component analysis

A groundbreaking study demonstrated that "SKIL promoted tumorigenesis and immune escape of NSCLC cells through upregulation of TAZ/autophagy axis and inhibition on downstream STING pathway" , providing a methodological framework for similar investigations in other cancer types.

What are the technical challenges in studying SKIL-protein interactions?

Studying SKIL-protein interactions presents several technical challenges that researchers should address through careful experimental design:

• Multiple Isoform Complexity:

  • SKIL exists in at least four isoforms (SnoN, SnoN2, SnoI, and SnoA)

  • Choose antibodies that recognize the specific isoform of interest or all isoforms as appropriate

  • Validate isoform-specific detection using overexpression systems

• Co-Immunoprecipitation Optimization:

  • When investigating SKIL interactions with partners like TAZ:

    • Use protein A-Sepharose beads coupled with anti-SKIL antibody (e.g., 19218-1-AP)

    • Include appropriate detergent conditions to maintain interactions while reducing background

    • Confirm specificity with reciprocal IPs and knockdown controls

• Subcellular Fractionation Considerations:

  • Given SKIL's differential localization between normal and cancer cells , subcellular fractionation should be performed when analyzing interaction partners

  • Include controls for cross-contamination between nuclear and cytoplasmic fractions

• Antibody Validation Concerns:

  • Some SKIL antibodies have been omitted from research platforms due to inconsistency issues

  • For example, HPA013920 was omitted due to overlapping antigen with other antibodies targeting the same gene

  • Cross-validate findings using multiple antibodies when possible

What factors affect SKIL antibody performance in Western blot applications?

Several critical factors can affect the performance of SKIL antibodies in Western blot applications:

• Sample Preparation:

  • Protein degradation: Use fresh samples with complete protease inhibitor cocktails

  • Denaturing conditions: SKIL detection may be sensitive to reducing agent concentration

  • Loading amount: Optimal protein load ranges from 10-30 μg total protein for cell lysates

• Transfer Efficiency:

  • Given SKIL's relatively high molecular weight (77 kDa), longer transfer times or lower percentage gels may be required

  • Consider using PVDF membranes for higher protein binding capacity compared to nitrocellulose

• Blocking and Antibody Incubation:

  • Test both milk and BSA-based blocking buffers; some epitopes may be masked by certain blocking agents

  • Primary antibody incubation at 4°C overnight typically yields better results than shorter incubations

  • Storage buffer (PBS with 0.02% sodium azide and 50% glycerol, pH 7.3) may affect performance in some buffer systems

• Expected Banding Pattern:

  • Primary band at 77 kDa (calculated and observed molecular weight)

  • Potential visualization of multiple isoforms depending on cell type and antibody specificity

  • Possible additional bands may represent post-translationally modified forms of SKIL

If inconsistent results are observed, consider testing multiple antibodies such as 19218-1-AP (Proteintech), DF3088 (Affinity), or A04131-1 (Boster) to determine which performs best in your experimental system .

How can I improve SKIL detection in immunohistochemistry applications?

Optimizing SKIL detection in immunohistochemistry requires attention to several methodological details:

• Antigen Retrieval Optimization:

  • Compare TE buffer pH 9.0 (recommended primary method) with citrate buffer pH 6.0 (alternative method)

  • Optimize retrieval time (typically 15-20 minutes) and temperature

  • For challenging samples, consider testing enzymatic retrieval methods

• Signal Amplification Options:

  • For tissues with low SKIL expression, implement tyramide signal amplification

  • Consider using polymer-based detection systems rather than ABC methods for improved sensitivity

  • Balance amplification with potential increases in background staining

• Background Reduction Strategies:

  • Implement endogenous peroxidase blocking (3% H₂O₂, 10 minutes)

  • Add avidin/biotin blocking for biotin-based detection systems

  • Include protein blocking step with 5-10% normal serum from the same species as the secondary antibody

  • Titrate antibody concentration to minimize background while maintaining specific signal

• Tissue-Specific Considerations:

  • For endometrial cancer tissue (positive control), optimize fixation time

  • For tissues with high endogenous biotin (liver, kidney), use non-biotin detection systems

  • Consider dual staining with subcellular markers to confirm localization pattern differences between normal and cancer tissues

The recommended dilution range for SKIL antibodies in IHC applications is 1:50-1:500, but this should be empirically determined for each tissue type and fixation method .

What approaches can resolve discrepancies between different SKIL antibodies?

When facing discrepancies between different SKIL antibodies, a systematic analytical approach is necessary:

• Epitope Mapping Analysis:

  • Compare the immunogens used for each antibody

  • 19218-1-AP uses SKIL fusion protein Ag5282

  • A04131-1 uses a 16 amino acid synthetic peptide from near the amino terminus

  • Antibodies targeting different epitopes may recognize distinct isoforms or conformations

• Validation Through Multiple Approaches:

  • Implement SKIL knockdown/knockout controls with each antibody

  • Compare reactivity with recombinant SKIL protein standards

  • Perform peptide competition assays when blocking peptides are available

  • Use alternative detection methods (mass spectrometry) for critical findings

• Cross-Platform Confirmation:

  • Compare antibody performance across multiple applications (WB, IP, IHC)

  • Some antibodies may perform well in one application but poorly in others

  • Correlate protein detection with mRNA expression data when possible

• Review Published Validation Data:

  • Check for published applications of specific antibody clones

  • 19218-1-AP has been cited in multiple publications for various applications

  • Consider antibody validation resources such as the Human Protein Atlas, which has documented issues with some SKIL antibodies (e.g., HPA013920 was omitted due to antigen overlap concerns)

When publishing results, clearly document which antibody was used, including catalog number and dilution, to facilitate reproducibility across laboratories.

How can SKIL antibodies advance our understanding of its role in cancer immunotherapy resistance?

Recent discoveries about SKIL's involvement in immune escape mechanisms open new avenues for cancer immunotherapy research. Methodological approaches to investigate this include:

• Correlation Studies:

  • Use SKIL antibodies to analyze expression in pre- and post-immunotherapy patient samples

  • Correlate SKIL levels with response rates and infiltrating immune cell populations

  • Implement multiplex IHC to simultaneously assess SKIL and immune checkpoint molecules

• Mechanistic Investigations:

  • Explore how SKIL modulates PD-L1 expression through TGF-β pathway interactions

  • Investigate the SKIL-TAZ-autophagy axis in relation to antigen presentation machinery

  • Study SKIL's impact on STING pathway activation in response to immunotherapy

• Therapeutic Strategy Development:

  • Test combinations of SKIL inhibition with immune checkpoint blockade

  • Develop assays to monitor SKIL activity as a biomarker for immunotherapy response

  • Explore the potential for SKIL antibodies in targeted protein degradation approaches

The foundational study showing SKIL's role in tumor immune escape suggests it may be a valuable therapeutic target or biomarker for immunotherapy resistance .

What considerations are important when integrating SKIL protein detection with multi-omics approaches?

As research moves toward integrated multi-omics approaches, specific methodological considerations for SKIL analysis include:

• Proteogenomic Integration:

  • Compare SKIL protein levels (antibody-based detection) with mRNA expression (RNA-seq)

  • Account for potential post-transcriptional regulation explaining discrepancies

  • Consider the impact of different SKIL isoforms on correlation analyses

• Single-cell Analysis Adaptations:

  • Optimize SKIL antibodies for mass cytometry (CyTOF) applications

  • Validate antibodies for compatibility with cell fixation methods used in single-cell protocols

  • Develop multiplex panels that include SKIL along with TGF-β pathway components

• Spatial Proteomics Approaches:

  • Adapt SKIL antibodies for imaging mass cytometry or multiplexed ion beam imaging

  • Validate sensitivity and specificity in tissue sections with known expression patterns

  • Compare subcellular localization data with standard IF/IHC findings

• Functional Proteomics Considerations:

  • Develop proximity labeling approaches to map SKIL interactome

  • Optimize antibodies for chromatin immunoprecipitation to assess SKIL's role in transcriptional regulation

  • Validate SKIL phosphorylation-specific antibodies for signaling studies